Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt–Jakob disease

B Van Everbroeck, A J E Green, E Vanmechelen, H Vanderstichele, P Pals, R Sanchez-Valle, N Cuadrado Corrales, J-J Martin, P Cras

**Objective:** To determine the concentrations of microtubule associated protein tau and multiple phosphorylated tau epitopes in the cerebrospinal fluid of patients with sporadic Creutzfeldt–Jakob disease (sCJD), dementias, and controls, in order to evaluate their diagnostic use and clinical relevance.

**Methods:** The CSF concentrations of total tau and phosphorylated tau at epitope 181 were determined by enzyme linked immunosorbent assay in 66 definite and nine probable sCJD patients, and in 97 controls. Other phosphorylated tau epitopes were investigated by western blot.

**Results:** In the sCJD population, determination of 14-3-3 protein and total tau protein concentrations was of the highest diagnostic value, with a sensitivity of 96% and 92%, respectively, and a specificity of 94% and 97%. Two distinct subgroups could be identified among the 75 sCJD patients based on the detection of phosphorylated tau at threonine 181 and serines 199, 202, and 404. A high phosphorylated tau concentration was clinically correlated with a significantly shorter disease duration, early onset of akinetic mutism, and a higher rate of typical EEGs (p < 0.05).

**Conclusions:** Although the determination of phosphorylated tau levels cannot be used as a diagnostic biomarker, it may prove useful for estimating the prognosis of an sCJD patient. These experiments reconfirm that sCJD is a disease with a complex pathology.

Creutzfeldt–Jakob disease (CJD) is a rapidly progressive and ultimately fatal disorder thought to be caused by prions. At present, a definite diagnosis can only be made at necropsy by neuropathological examination of brain tissue. The most common form of CJD is the sporadic type (sCJD), with an incidence of 1/100,000 inhabitants per year, accounting for 85% of all known CJD patients. The polymorphism at codon 129 of the prion protein gene (PRNP129) is known to modulate the clinical characteristics and neuropathological phenotype. PRNP129 encodes for either a methionine (M) or a valine (V). The prion glycosylation pattern (PrP type) determined by western blot analysis shows two different forms. These data serve as the basis for the classification of sCJD into seven subgroups: MM1, MM2-thalamic, MM2-thalamic, MV1, MV2, VV1, and VV2.

Cerebrospinal fluid (CSF) contains several proteins that can aid in the clinical diagnosis of CJD. Immunodetection studies of 14-3-3 protein and tau protein have suggested that these are sensitive and specific biomarkers. On the other hand, normal or raised levels of full length CSF β amyloid (Aβ1–42) have been found in patients suffering from neurological disorders that clinically resemble CJD and yield a positive 14-3-3 or tau result, in contrast to the decreased levels of Aβ1–42 found in sCJD patients.

Tau protein and its phosphorylated form are known to be involved in many neurodegenerative disorders. For instance, hyperphosphorylated tau is the most important subunit of neurofibrillary tangles. Finally, in most Alzheimer and sCJD patients, an increased concentration of total CSF tau protein has been reported.

In this study, we investigated whether a new ELISA technique to measure phosphorylated tau at epitope 181 in CSF could be a sensitive and specific biomarker for sCJD. Further investigations into possible associations between phosphorylated tau levels and the clinical phenotype, genotype, and other biochemical markers in sCJD were also carried out to examine the possible role of tau phosphorylation in CJD disease pathogenesis.

**METHODS**

CSF was studied in the following patients: 75 with sCJD (mean (SD) age, 64 (8) years); 34 with Alzheimer's disease (72 (8) years); 33 with other dementia (69 (6) years); and 30 controls (58 (12) years). The other dementia group included cases of viral encephalitis (n = 9), Guillain–Barre syndrome (n = 3), dizziness (n = 2), multiple sclerosis (n = 7), polyradiculopathy (n = 4), and stroke (n = 5). Diagnosis was always made according to classical criteria.

The CSF concentrations of 14-3-3 protein and Aβ1–42 were determined as previously described. Tau protein levels were measured in duplicate by an enzyme linked immunosorbent assay (ELISA) (Innotest hTAU-Ag, Innogenetics, Ghent, Belgium). A value of 1350 pg/ml was used as the cut off for a positive test. The concentration of tau phosphorylated at threonine 181 (p181T phospho-tau) was measured in duplicate using the research version of the Innotest Phospho-Tau181 assay. For standardisation, a phosphorylated synthetic peptide was used in this test. As the determination of total tau uses recombinant tau as standard with a calculated molecular weight of 41 063 kDa, it was possible to convert pg/ml to pM. The use of these different standards and antibodies in the detection of tau and phospho-tau has resulted, both in this study and in previous work, in seemingly higher concentrations of phospho-tau than tau when comparing the results in a single patient. This effect has no direct influence on the evaluation of the results.

Both monoclonal mouse antibodies AT180 (threonine 231–235) and AT270 (threonine 181, Innogenetics Inc) and rabbit polyclonal antibodies 44–768 (serine 199–202), 44–738 (threonine 205), 44–726 (threonine 231), 44–7580 (serine 199–202), 44–768 (serine 202–205), and 44–768 (serine 205–208) (Biosource Inc, Cammarillo, California, USA) were used in this study. For the determination of phospho-tau in CSF, according to the manufacturer's instructions and using an identical standard in all experiments. The resulting signal was measured and quantified using a Kodak image station 440 and accompanying software. These measurements were used to calculate the ratio of each signal to the standard, while the results were expressed as arbitrary units (AU).
When formalin fixed, paraffin embedded brain tissue was available, neurofibrillary tangles, prion deposition, and amyloid β plaques were detected immunohistochemically using AT8 (Innogenetics Inc.), 3F4 (Senetec, St Louis, Missouri, USA), and 4G8 (Senetec) monoclonal antibodies, respectively. The prion protein codon 129 polymorphism and the prion protein strain were determined as described previously.44

Statistics

For all statistical analyses, a cut off probability (p) value of 0.05 was used to determine statistical significance. The results of the ELISA and western blot determinations were examined using the Kolmogorov–Smirnov test (InStat software package), which showed that the results obtained did not have a normal distribution (p < 0.05). Therefore, all results were expressed as medians and centiles, and all analyses were performed using the Mann–Whitney U test. The correlation between groups was calculated using the Pearson product moment coefficient of correlation. The analysis of the different features between the two CJD subgroups was done using Fisher’s exact test. Significant values are indicated in bold.

RESULTS

In sCJD patients, 14-3-3 and the total tau concentration resulted in the highest sensitivity and specificity. Positive 14-3-3 results were identified in 72 cases of sCJD, one of other dementia, and two controls. The analysis of phospho-tau epitopes by immunoblot showed an increased signal for sCJDhigh in some but not all investigated epitopes (fig 1). A significant difference was observed when comparing the neuropathological lesions between the patients formerly classified as MM1 patients who were found to be either sCJDhigh or sCJDlow (table 1).

DISCUSSION

We investigated the concentration of tau and phosphotau in CSF from sCJD and control patients using ELISA and western blot. Two significantly different sCJD subgroups (sCJDhigh and sCJDlow) were identified, based on their p181T phospho-tau concentrations. The sCJDlow subgroup was characterised by an extremely high concentration of p181T phospho-tau compared with the sCJDhigh and controls. All sCJDlow patients were associated with early akinetic mutism and short disease duration (maximum four months).

The sCJDhigh group showed increased values of certain phospho-tau epitopes— independent of all known disease modifiers but associated with duration of the disease—pointing to a difference in the rate of disease progression. In these “acute” CJD cases neurodegeneration must progress at an increased rate, releasing both tau and phospho-tau in the extracellular space. We hypothesise that in sCJDhigh patients, oxidative stress activates the specific kinases, which results in increased levels of phospho-tau. These pathways might lead to the additional (extra-)cellular phosphorylation of tau, retrieved in the CSF. In our series, only the epitopes pT181, pS199–202, and pS404 were found to be significantly hyperphosphorylated. Previous experiments have shown that epitope specific phosphorylation is induced by certain kinases,15 and the glycogen synthase kinase 3β specifically phosphorylates the epitopes found in our study.16 Conversely, reduced activity of phosphatases or greater resistance to dephosphorylation could also contribute to the observed effect. Whether the difference in
phosphorylation reflects mainly kinase or mainly phosphatase activity and whether it plays a physiologically significant role must be addressed in future studies.

Although the results we obtained in this study indicate that determination of the p181T phospho-tau concentration cannot be employed as a diagnostic biomarker, it could be useful for estimating prognosis (suspected disease duration) of an sCJD patient. For use in a clinical setting, however, the test validity should be examined prospectively. Finally, the determination of the p181T phospho-tau concentration could conceivably be used in future clinical trials to measure the effect of a drug on disease progression.

ACKNOWLEDGEMENTS

We thank all physicians who sent us the CSF samples and clinical information on suspected CJD patients and control cases. We are also grateful to Karen De Vreese and Annelles De Brauwer (Innogenetics, Ghent, Belgium) for useful discussions, as well as Tessa James (Innogenetics, Ghent, Belgium) for editorial assistance. The Vlaams Instituut ter Bevordering van het Wetenschappelijk–Technologisch Onderzoek in de Industrie (IWT) and the Fund for Scientific Research (FWO) supported this research. The Innogenest Phospho-Tau 181 assay, which made this study possible, was provided free of charge to BE and PC by Innogenetics nv. EVM and HVDS are employees of the company Innogenetics, Belgium (IWT). Correspondence to: Dr P Cras, Laboratory of Neurobiology, Born Bunge Bank, Complutesis University, Madrid, Spain Centre for Epidemiology, Carlos III Institute of Health and Research Brain B Van Everbroeck, P Pals, J-J Martin, P Cras, authors’ affiliations.


Baron Constantin von Economo was the first Austrian to obtain a pilot’s diploma. He served in aviation with distinction and supported preparations for the International Aviation Congress held in Vienna. Economo, of Greek parentage, was brought up in Austrian Trieste. He enrolled in engineering school, but after two years began his medical training in Vienna and received his medical degree in 1901. In 1906, Economo became an assistant to Julius Wagner Jauregg, psychiatrist in Vienna. Wagner Jauregg received the Nobel Prize in 1927 for his use of malaria inoculation to induce fever in patients with syphilis in an attempt to cure the disease.

In his early studies, Economo concentrated on the anatomy and physiology of the midbrain, pons, and trigeminal nerve pathway. In 1930 he described (with L Horn) the upper temporal lobe on the left as usually larger than on the right. A major contribution of his was The Cerebral Cortex in Adult Man published in 1925 but he is eponymously known for his description of encephalitis lethargica, also known as Von Economo’s Disease. As well as the clinical features, Economo also discussed the pathology and histology. The disease first appeared in Romania in 1915 and raged globally until 1927. Encephalitis lethargica was once a major cause of death and economic loss.

Phospho-tau in CSF of CJD patients

81

Received 21 December 2001
In revised form 27 March 2002
Accepted 27 March 2002

REFERENCES